Anna Månberg

Anna Månberg

Auto-generated profile, based on publicly available information

Anna Månberg

Department of Protein Science, KTH Royal Institute of Technology, SciLifeLab, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Science Signaling
Verified
Journal Article
Closed access
PDF file
MUMathias Uhlen
Mathias Uhlen
MKMax J. Karlsson
Max J. Karlsson
AHAndreas Hober
Andreas Hober
ASAnne-Sophie Svensson
Anne-Sophie Svensson
JSJulia Scheffel
Julia Scheffel
ÅSÅsa Sivertsson
Åsa Sivertsson
A database provides information on the relative abundances and locations of human proteins that are predicted to be secreted.

8 October 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
ARAnn-Sofie Rudberg
Ann-Sofie Rudberg
SHSebastian Havervall
Sebastian Havervall
AMAnna Månberg
Anna Månberg
AFAugust Jernbom Falk
August Jernbom Falk
KAKatherina Aguilera
Katherina Aguilera
CTCharlotte Thålin
Charlotte Thålin
SARS-CoV-2 may pose an occupational health risk to healthcare workers. Here, we report the seroprevalence of SARS-CoV-2 antibodies, self-reported symptoms and occupational exposure to SARS-CoV-2 among healthcare workers at a large acute care hospital in Sweden. The seroprevalence of IgG antibodies against SARS-CoV-2 was 19.1% among the 2149 healthcare workers recruited between April 14th and May 8th 2020, which was higher than the reported regional seroprevalence during the same time period. Symptoms associated with seroprevalence were anosmia (odds ratio (OR) 28.4, 95% CI 20.6–39.5) and ageusia (OR 19.2, 95% CI 14.3–26.1). Seroprevalence was also associated with patient contact (OR 2.9, 95% CI 1.9–4.5) and covid-19 patient contact (OR 3.3, 95% CI 2.2–5.3). These findings imply an occupational risk for SARS-CoV-2 infection among healthcare workers. Continued measures are warranted to assure healthcare workers safety and reduce transmission from healthcare workers to patients and to the community.

15 April 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AMAnna Månberg
Anna Månberg
NSNathan Skene
Nathan Skene
FSFolkert Sanders
Folkert Sanders
MTMarta Trusohamn
Marta Trusohamn
JRJulia Remnestål
Julia Remnestål
SLSebastian A. Lewandowski
Sebastian A. Lewandowski

27 September 2021 in Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
SHSebastian Havervall
Sebastian Havervall
HNHenry Ng
Henry Ng
AFAugust Jernbom Falk
August Jernbom Falk
NGNina Greilert‐Norin
Nina Greilert‐Norin
AMAnna Månberg
Anna Månberg
CTCharlotte Thålin
Charlotte Thålin
Background: Emerging data support detectable immune responses for months after severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection and vaccination, but it is not yet established to what degree and for how long protection against reinfection lasts.Methods: We investigated SARS‐CoV‐2‐specific humoral and cellular immune responses more than 8 months post‐asymptomatic, mild and severe infection in a cohort of 1884 healthcare workers (HCW) and 51 hospitalized COVID‐19 patients. Possible protection against SARS‐CoV‐2 reinfection was analyzed by a weekly 3‐month polymerase chain reaction (PCR) screening of 252 HCW that had seroconverted 7 months prior to start of screening and 48 HCW that had remained seronegative at multiple time points.Results: All COVID‐19 patients and 96% (355/370) of HCW who were anti‐spike IgG positive at inclusion remained anti‐spike IgG positive at the 8‐month follow‐up. Circulating SARS‐CoV‐2‐specific memory T cell responses were detected in 88% (45/51) of COVID‐19 patients and in 63% (233/370) of seropositive HCW. The cumulative incidence of PCR‐confirmed SARS‐CoV‐2 infection was 1% (3/252) among anti‐spike IgG positive HCW (0.13 cases per 100 weeks at risk) compared to 23% (11/48) among anti‐spike IgG negative HCW (2.78 cases per 100 weeks at risk), resulting in a protective effect of 95.2% (95% CI 81.9%–99.1%).Conclusions: The vast majority of anti‐spike IgG positive individuals remain anti‐spike IgG positive for at least 8 months regardless of initial COVID‐19 disease severity. The presence of anti‐spike IgG antibodies is associated with a substantially reduced risk of reinfection up to 9 months following asymptomatic to mild COVID‐19.

7 August 2023 in Molecular & Cellular Proteomics
Verified
Journal Article
Open access
CTCharlotte E. Teunissen
Charlotte E. Teunissen
LKLeighann Kimble
Leighann Kimble
SBSherif Bayoumy
Sherif Bayoumy
KBKatharina Bolsewig
Katharina Bolsewig
FBFelicia Burtscher
Felicia Burtscher
HZHenrik Zetterberg
Henrik Zetterberg
Neurodegenerative dementias are progressive diseases that cause neuronal network breakdown in different brain regions often because of accumulation of misfolded proteins in the brain extracellular matrix, such as amyloids or inside neurons or other cell types of the brain. Several diagnostic protein biomarkers in body fluids are being used and implemented, such as for Alzheimer's disease. However, there is still a lack of biomarkers for co-pathologies and other causes of dementia. Such biofluid-based biomarkers enable precision medicine approaches for diagnosis and treatment, allow to learn more about underlying disease processes, and facilitate the development of patient inclusion and evaluation tools in clinical trials. When designing studies to discover novel biofluid-based biomarkers, choice of technology is an important starting point. But there are so many technologies to choose among. To address this, we here review the technologies that are currently available in research settings and, in some cases, in clinical laboratory practice. This presents a form of lexicon on each technology addressing its use in research and clinics, its strengths and limitations, and a future perspective.

15 June 2021 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SBSofia Bergström
Sofia Bergström
JRJulia Remnestål
Julia Remnestål
JYJamil Yousef
Jamil Yousef
JOJennie Olofsson
Jennie Olofsson
IMIoanna Markaki
Ioanna Markaki
PNPeter Nilsson
Peter Nilsson
Objective: Decreased amyloid beta (Aβ) 42 together with increased tau and phospho‐tau in cerebrospinal fluid (CSF) is indicative of Alzheimer’s disease (AD). However, the molecular pathophysiology underlying the slowly progressive cognitive decline observed in AD is not fully understood and it is not known what other CSF biomarkers may be altered in early disease stages.Methods: We utilized an antibody‐based suspension bead array to analyze levels of 216 proteins in CSF from AD patients, patients with mild cognitive impairment (MCI), and controls from two independent cohorts collected within the AETIONOMY consortium. Two additional cohorts from Sweden were used for biological verification.Results: Six proteins, amphiphysin (AMPH), aquaporin 4 (AQP4), cAMP‐regulated phosphoprotein 21 (ARPP21), growth‐associated protein 43 (GAP43), neurofilament medium polypeptide (NEFM), and synuclein beta (SNCB) were found at increased levels in CSF from AD patients compared with controls. Next, we used CSF levels of Aβ42 and tau for the stratification of the MCI patients and observed increased levels of AMPH, AQP4, ARPP21, GAP43, and SNCB in the MCI subgroups with abnormal tau levels compared with controls. Further characterization revealed strong to moderate correlations between these five proteins and tau concentrations.Interpretation: In conclusion, we report six extensively replicated candidate biomarkers with the potential to reflect disease development. Continued evaluation of these proteins will determine to what extent they can aid in the discrimination of MCI patients with and without an underlying AD etiology, and if they have the potential to contribute to a better understanding of the AD continuum.